Obesity, Metabolic Syndrome, and Cardiovascular Risk in Gluten-Free Followers Without Celiac Disease in the United States: Results from the National Health and Nutrition Examination Survey 2009–2014
- 1.3k Downloads
Despite unclear benefits of gluten-free diets (GFD) in the general population, gluten-free followers without medical indications are driving the market. Few studies have investigated health benefits of GFD in the general population.
To estimate metabolic and cardiovascular disease (CVD) risk profiles among gluten-free followers without celiac disease (CD).
Data were obtained from the National Health and Nutrition Examination Survey (NHANES) 2009–2014. There were 13,523 persons without CD who had GFD information. People with known CVD were excluded. We compared gluten-free followers without CD and the general population by selective metabolic and CVD risk profiles using survey-weighted generalized logistic regression.
There were 155 gluten-free followers without CD and CVD, corresponding to a weighted prevalence of 1.3% (3.2 million Americans). Gluten-free followers tended to be women and have a smaller waist circumference and higher HDL cholesterol. They also had a lower BMI with a borderline p value (0.053) and significant self-reported weight loss (−1.33 kg) over one year. Moreover, gluten-free followers were more likely to consider their weight appropriate. There was no statistical difference by age, smoking, hypertension, total cholesterol, triglyceride cholesterol, HbA1c, or fasting glucose. Despite a lower probability of having metabolic syndrome (33.0 vs 38.5%) and lower 10-year CVD risk score (4.52 vs 5.70%) in gluten-free followers, there was no statistical difference.
Although being on a GFD may be beneficial in weight management, there was no significant difference in terms of prevalence of metabolic syndrome and CVD risk score in gluten-free followers without CD.
KeywordsGluten-free diet Obesity Metabolic syndrome Cardiovascular risk
HSK and SKA are involved in study and design. All authors are involved in acquisition, analysis, or interpretation of data. All authors are involved in drafting of the manuscript. All authors are involved in critical revision of the manuscript for important intellectual content. HSK is involved in statistical analysis. All authors are involved in administrative, technical, or material support. HSK, MFD, NK, MF, SKA are involved in study supervision. Dr. H.S. Kim had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors approved the final version of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
- 1.MarketsandMarkets. Gluten-Free Products Market by Type (Bakery Products, Pizzas & Pastas, Cereals & Snacks, Savories, and Others), Source (Oilseeds & Pulses, Rice & Corn, Dairy & Meat Products, and Other Crops), & by Region—Global Trends & Forecast to 2020. (http://www.marketsandmarkets.com/Market-Reports/gluten-free-products-market-738.html).
- 2.Topper A. Non-celiacs drive gluten-free market growth. Mintel. 2014; http://www.mintel.com/blog/food-market-news/gluten-free-consumption-trends.
- 4.Gaesser G, Angadi S. Navigating the gluten-free boom. J Am Acad Phys Assist. 2015;28:1–7.Google Scholar
- 9.Kurppa K, Paavola A, Collin P, et al. Benefits of a gluten-free diet for asymptomatic patients with serologic markers of celiac disease. Gastroenterology. 2014;147:610–617 e611.Google Scholar
- 17.NCHS. 2013–2014 Data Documentation, Codebook, and Frequencies: Medical Conditions (MCQ_H). (https://wwwn.cdc.gov/Nchs/Nhanes/2013-2014/MCQ_H.htm).
- 18.Rubio-Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE. The prevalence of celiac disease in the United States. Am J Gastroenterol. 2012;107:1538–1544; quiz 1537, 1545.Google Scholar
- 19.Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1–452.Google Scholar
- 21.NHLBI. Assessing cardiovascular risk: systemic evidence review from the risk assessment work group. 2013 (https://www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/risk-assessment.pdf).
- 22.NCHS. 2009–2010 Data Documentation, Codebook, and Frequencies: Weight History (WHQ_F). https://wwwn.cdc.gov/Nchs/Nhanes/2009-2010/WHQ_F.htm-WHQ030.
- 24.Breslow NE, Day NE. Statistical methods in cancer research. Volume II–The design and analysis of cohort studies. IARC Sci Publ. 1987;82:1–406.Google Scholar
- 46.Gluten: going against the grain?. Lancet Gastroenterol Hepatol 2016;1:85.Google Scholar